Plain-English translation of NCT06604260 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are testing whether a new imaging scan called 68Ga-FAPi PET/CT can help detect scarring (fibrosis) in the intestines of people with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This scan works by detecting special cells that appear when scarring develops. The study will compare what the scan shows with what doctors find in tissue samples taken during routine procedures.
Scarring of the intestines is a serious problem for many people with inflammatory bowel disease, but doctors don't currently have a good way to detect it early. This trial is testing whether this new scan could help identify scarring before it causes severe complications, potentially leading to better treatment and care.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the new 68Ga-FAPi PET/CT imaging scan, which is a type of advanced medical imaging that takes pictures of your intestines. During this scan, you would be given a small amount of tracer material and then lie still inside a scanner for a period of time. Researchers will compare the results of this scan with tissue samples from biopsies or surgery to better understand how well the scan detects intestinal scarring.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
Netherlands
Testing effectiveness
Sponsor
Dalia Lartey
Enrollment target
~20 participants
Started
August 2023
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dalia A Lartey, MD
Amsterdam UMC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.